Canada's health authorities are planning to suspend the sale of Allergan's Biocell breast implants as a precautionary measure.
The implants have been linked to a form of cancer with anaplastic large cell lymphoma, BIA-ALCL, which grows in the scar tissue surrounding the breast implant.
Health Canada will suspend the implants' license until a study assessing their effects is finalized.
"Health Canada initiated the review because of an increase in Canadian and international cases of BIA-ALCL," the government agency said in a statement last week.
"There have been 28 confirmed Canadian cases of BIA-ALCL — 24, or 86 percent — of the illnesses were linked to Allergan's Biocell breast implant," it added.